Macular Degeneration Trial, Recruiting (NCT06445322)

Macular Degeneration Trial, Recruiting NCT06445322 Sponsor: Ascidian Therapeutics, Inc Condition: Macular Degeneration

Printed from Voxsanity (voxsanity.com.au) — NCT06445322 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Macular Degeneration

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been found to have a change (mutation) in a gene called ABCA4
You have been diagnosed with an eye condition linked to the ABCA4 gene, such as Stargardt disease type 1 or a condition called cone-rod dystrophy

Who may not be able to join:

You have a gene change in a different gene (not ABCA4) that is known to cause cone-rod dystrophy or Stargardt disease
You have an eye (retinal) disease that is not caused by the ABCA4 gene
You have a health condition (affecting your whole body or your eyes), a mental health condition (including substance use disorder), or test results that, in the opinion of the trial doctors, could make it unsafe for you to take part, affect your ability to attend regular study visits, or affect the results of the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alia Rashid, Ascidian Therapeutics

Phone: 207-573-0412

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06445322

Sponsor: Ascidian Therapeutics, Inc

Phase: Not Applicable

Status: Recruiting

Condition: Macular Degeneration

Trial contact: 207-573-0412

More information: https://clinicaltrials.gov/study/NCT06445322

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been found to have a change (mutation) in a gene called ABCA4
You have been diagnosed with an eye condition linked to the ABCA4 gene, such as Stargardt disease type 1 or a condition called cone-rod dystrophy

Who may not be able to join:

You have a gene change in a different gene (not ABCA4) that is known to cause cone-rod dystrophy or Stargardt disease
You have an eye (retinal) disease that is not caused by the ABCA4 gene
You have a health condition (affecting your whole body or your eyes), a mental health condition (including substance use disorder), or test results that, in the opinion of the trial doctors, could make it unsafe for you to take part, affect your ability to attend regular study visits, or affect the results of the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Ascidian Therapeutics, Inc

Registry

ClinicalTrials.gov

Start date

20 June 2024

Est. completion

31 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Confirm mutations in the ABCA4 gene; Confirm the absence of pathogenic mutations in genes known to cause retinal disease other than ABCA4-related retinopathy; Measure BCVA and LLVA; Measure the area of retinal atrophy; Measure baseline retinal structure; Historical FAF or OCT images; Historical BCVA/LLVA measurements

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov